All In Biotech

Drug Trial Radar · NCT04492475

Adaptive COVID-19 Treatment Trial 3 (ACTT-3)

A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-3)

Last checked: Nov 20, 2026Latest source record: Mar 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 969 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

969

Actual

Start

Aug 5, 2020

Primary completion

Dec 21, 2020

Study completion Dec 21, 2020

Sponsor

Sponsor type
NIH
First posted
Jul 30, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ACTT-3 will evaluate the combination of interferon beta-1a and remdesivir compared to remdesivir alone. Subjects will be assessed daily while hospitalized. If the subjects are discharged from the hospital, they will have a study visit at Days 15, 22, and 29. For discharged subjects, it is preferred that the Day 15 and 29 visits are in person to obtain safety laboratory tests and oropharyngeal (OP) swab and blood (serum only) samples for secondary research as well as clinical outcome data. However, infection control or other restrictions may limit the ability of the subject to return to the clinic. In this case, these visits may be conducted by phone, and only clinical data will be obtained. The Day 22 visit does not have laboratory tests or collection of samples and is conducted by phone. The primary outcome is time to recovery by Day 29.

Conditions

  • COVID-19

Interventions

  • Interferon beta-1aDrug

    Rebif (R) is a purified 166 amino acid human interferon beta glycoprotein with an amino acid sequence identical to natural fibroblast derived human interferon beta. Each 0.5 mL prefilled syringe contains 44 mcg of interferon beta-1a, 4 mg human albumin, USP; 27.3 mg mannitol, USP; 0.4 mg sodium acetate; and water for injection, USP.

  • PlaceboOther

    The interferon beta-1a placebo contains either 0.5 mL 0.9% normal saline or 0.5 mL sterile water for injection.

  • RemdesivirDrug

    Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Recovery for Participants With Baseline Ordinal Score 4, 5 and 6Time frame: Day 1 through Day 29
  2. Time to Recovery for Participants With Baseline Ordinal Score 4, 5 and 6 by RaceTime frame: Day 1 through Day 29
  3. Time to Recovery for Participants With Baseline Ordinal Score 4, 5 and 6 by EthnicityTime frame: Day 1 through Day 29
  4. Time to Recovery for Participants With Baseline Ordinal Score 4, 5 and 6 by SexTime frame: Day 1 through Day 29

Locations

64 sites in 5 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham School of Medicine - Infectious Disease

    Birmingham, Alabama

  • UCSF Fresno Center for Medical Education and Research - Clinical Research Center

    Fresno, California

  • University of California San Diego Health - Jacobs Medical Center

    La Jolla, California

  • University of California Los Angeles Medical Center - Westwood Clinic

    Los Angeles, California

  • University of California Irvine Medical Center - Infectious Disease

    Orange, California

  • VA Palo Alto Health Care System - Infectious Diseases

    Palo Alto, California

  • Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases

    Palo Alto, California

  • University of California Davis Medical Center - Internal Medicine - Infectious Disease

    Sacramento, California

  • Naval Medical Center San Diego - Infectious Disease Clinic

    San Diego, California

  • University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of HIV, ID, and Global Medicine

    San Francisco, California

  • Cedars Sinai Medical Center

    West Hollywood, California

  • Eastern Colorado Health Care System

    Aurora, Colorado

  • Denver Health Division of Hospital Medicine - Main Campus

    Denver, Colorado

  • University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine

    Gainesville, Florida

  • University of Florida Health - Jacksonville - Department of Emergency Medicine

    Jacksonville, Florida

  • University of Miami Miller School of Medicine - Infectious Diseases

    Miami, Florida

  • Emory Vaccine Center - The Hope Clinic

    Decatur, Georgia

  • Atlanta VA Medical Center - Infectious Diseases Clinic

    Decatur, Georgia

  • Tripler Army Medical Center (TAMC)

    Honolulu, Hawaii

  • Northwestern Hospital - Infectious Disease

    Chicago, Illinois

  • University of Illinois at Chicago Division of Infectious Diseases

    Chicago, Illinois

  • University of Iowa Hospitals & Clinics - Department of Internal Medicine

    Iowa City, Iowa

  • Ochsner Medical Center - Kenner - Department of Infectious Diseases

    Kenner, Louisiana

  • Southeast Louisiana Veterans Health Care System - Section of Infectious Diseases

    New Orleans, Louisiana

  • University of Maryland School of Medicine - Center for Vaccine Development - Baltimore

    Baltimore, Maryland

  • Johns Hopkins Hospital - Medicine - Infectious Diseases

    Baltimore, Maryland

  • Walter Reed National Military Medical Center

    Bethesda, Maryland

  • National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section

    Bethesda, Maryland

  • Massachusetts General Hospital - Infectious Diseases

    Boston, Massachusetts

  • University of Massachusetts Medical School - Infectious Diseases and Immunology

    Worcester, Massachusetts

  • University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine

    Minneapolis, Minnesota

  • Saint Louis University - Center for Vaccine Development

    St Louis, Missouri

  • University of Nebraska Medical Center - Infectious Diseases

    Omaha, Nebraska

  • University of New Mexico Clinical and Translational Science Center

    Albuquerque, New Mexico

  • New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology

    New York, New York

  • University of Rochester Medical Center - Vaccine Research Unit

    Rochester, New York

  • Montefiore Medical Center - Infectious Diseases

    The Bronx, New York

  • Duke Human Vaccine Institute - Duke Vaccine and Trials Unit

    Durham, North Carolina

  • Womack Army Medical Center - Pulmonary and Respiratory Services

    Fort Bragg, North Carolina

  • Kaiser Permanente Northwest - Center for Health Research

    Portland, Oregon

Showing 40 of 64 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.